Merck & Co Inc (MRK)
131.49
+0.77
(+0.59%)
USD |
NYSE |
Apr 26, 14:34
Merck Enterprise Value: 359.08B for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 359.08B |
| April 24, 2024 | 349.66B |
| April 23, 2024 | 349.36B |
| April 22, 2024 | 349.51B |
| April 19, 2024 | 346.57B |
| April 18, 2024 | 345.18B |
| April 17, 2024 | 345.53B |
| April 16, 2024 | 344.75B |
| April 15, 2024 | 347.61B |
| April 12, 2024 | 346.47B |
| April 11, 2024 | 347.51B |
| April 10, 2024 | 349.03B |
| April 09, 2024 | 348.93B |
| April 08, 2024 | 348.55B |
| April 05, 2024 | 352.17B |
| April 04, 2024 | 351.33B |
| April 03, 2024 | 357.01B |
| April 02, 2024 | 358.15B |
| April 01, 2024 | 359.77B |
| March 28, 2024 | 362.20B |
| March 27, 2024 | 361.69B |
| March 26, 2024 | 345.91B |
| March 25, 2024 | 345.38B |
| March 22, 2024 | 341.68B |
| March 21, 2024 | 341.10B |
| Date | Value |
|---|---|
| March 20, 2024 | 341.68B |
| March 19, 2024 | 337.51B |
| March 18, 2024 | 335.58B |
| March 15, 2024 | 335.78B |
| March 14, 2024 | 333.22B |
| March 13, 2024 | 337.40B |
| March 12, 2024 | 338.67B |
| March 11, 2024 | 338.95B |
| March 08, 2024 | 340.80B |
| March 07, 2024 | 342.04B |
| March 06, 2024 | 341.43B |
| March 05, 2024 | 339.10B |
| March 04, 2024 | 342.19B |
| March 01, 2024 | 349.56B |
| February 29, 2024 | 350.04B |
| February 28, 2024 | 352.68B |
| February 27, 2024 | 354.80B |
| February 26, 2024 | 354.32B |
| February 23, 2024 | 355.87B |
| February 22, 2024 | 355.39B |
| February 21, 2024 | 352.50B |
| February 20, 2024 | 350.60B |
| February 16, 2024 | 351.66B |
| February 15, 2024 | 348.50B |
| February 14, 2024 | 346.67B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
176.33B
Minimum
Mar 23 2020
362.20B
Maximum
Mar 28 2024
247.28B
Average
226.51B
Median
Aug 25 2020
Enterprise Value Benchmarks
| Amgen Inc | 198.03B |
| Johnson & Johnson | 360.21B |
| Eli Lilly and Co | 711.57B |
| Pfizer Inc | 201.07B |
| Moderna Inc | 32.05B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.226B |
| Revenue (Quarterly) | 14.63B |
| Total Expenses (Quarterly) | 16.34B |
| EPS Diluted (Quarterly) | -0.48 |
| Gross Profit Margin (Quarterly) | 73.26% |
| Profit Margin (Quarterly) | -8.38% |
| Earnings Yield | 0.11% |
| Operating Earnings Yield | 0.88% |
| Normalized Earnings Yield | 0.2425 |